21 Dec 2006 - MedImmune, Inc. announced that it has completed its sale of CytoGam(R) (cytomegalovirus immune globulin intravenous (human)) to ZLB Behring. As specified in the agreement executed November 8, 2006, ZLB Behring has made a one-time upfront payment of $50 million to MedImmune, plus equipment and inventory payments, for full worldwide rights to CytoGam. Further, an additional $70 million may be paid to MedImmune by ZLB Behring upon achievement of certain cumulative net sales milestones.
CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV). It is used to prevent CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart.
 |
www.bionity.com/news/e/60300 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/60300 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |